drugset / Trial / NCT07172919
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.
Timeline
- Start
- 2026-01-02
- Primary completion
- 2028-01-02
- Completion
- 2028-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab | Monoclonal antibody | — | Intravenous |
| Subject | Sotorasib | Small molecule | — | Oral |
Indications
No indication recorded.